About Tagomics

Tagomics develops a proprietary multiomic platform that utilizes genetic, epigenetic, and fragmentomic profiling to identify disease-associated biomarkers from various biological samples. This technology enables high-throughput and cost-effective diagnostics for early detection of colorectal and other common cancers, addressing the need for reliable biological markers sensitive to lifestyle and environmental factors.

```xml <problem> Current methods for detecting cancer biomarkers often lack sensitivity to lifestyle and environmental factors, and can be expensive and time-consuming. This can lead to delays in diagnosis and treatment, particularly for cancers like colorectal cancer that are influenced by environmental factors. </problem> <solution> Tagomics offers a multiomic platform that integrates genetic, epigenetic, and fragmentomic profiling to identify disease-associated biomarkers from biological samples. The platform uses advanced bioinformatic and machine learning approaches to provide insights into disease mechanisms and improve diagnostic accuracy. Tagomics' technology enables high-throughput and cost-effective multiomic disease profiling, with low sample input and automation capabilities. The platform is sample-agnostic and designed for reliable and reproducible results. </solution> <features> - Multiomic profiling platform integrating genetic, epigenetic, and fragmentomic data - Advanced bioinformatic and machine learning algorithms for biomarker discovery - High-throughput and cost-effective analysis - Low sample input requirements - Automatable workflow - Sample-agnostic design - Reliable and reproducible results - Interlace™ solution for multiomic profiling </features> <target_audience> The primary target audience includes researchers, clinicians, and pharmaceutical companies focused on early cancer detection and diagnosis, particularly for colorectal and other common cancers. </target_audience> ```

What does Tagomics do?

How much funding has Tagomics raised?

Tagomics has raised $10.1M.

Who founded Tagomics?

Tagomics was founded by Kirk Malloy and Rob Neely.

Kirk Malloy - Founder/CEO
Rob Neely - Co-founder/CSO

Funding

$10.1M

Employees

20 employees

Investors

Galaxy Ventures Illumina Ventures

Tagomics

202K+ followers

Updated 2 months ago

Funding

$10.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Current methods for detecting cancer biomarkers often lack sensitivity to lifestyle and environmental factors, and can be expensive and time-consuming. This can lead to delays in diagnosis and treatment, particularly for cancers like colorectal cancer that are influenced by environmental factors.

Solution

Tagomics offers a multiomic platform that integrates genetic, epigenetic, and fragmentomic profiling to identify disease-associated biomarkers from biological samples. The platform uses advanced bioinformatic and machine learning approaches to provide insights into disease mechanisms and improve diagnostic accuracy. Tagomics' technology enables high-throughput and cost-effective multiomic disease profiling, with low sample input and automation capabilities. The platform is sample-agnostic and designed for reliable and reproducible results.

Target Audience

The primary target audience includes researchers, clinicians, and pharmaceutical companies focused on early cancer detection and diagnosis, particularly for colorectal and other common cancers.

Features

Multiomic profiling platform integrating genetic, epigenetic, and fragmentomic data
Advanced bioinformatic and machine learning algorithms for biomarker discovery
High-throughput and cost-effective analysis
Low sample input requirements
Automatable workflow
Sample-agnostic design
Reliable and reproducible results
Interlace™ solution for multiomic profiling